These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30323555)

  • 1. A descriptive analysis of real-world treatment patterns of innovator (Remicade
    Yazici Y; Xie L; Ogbomo A; Ellis LA; Goyal K; Teeple A; Mutlu EA; Simsek I
    Biologics; 2018; 12():97-106. PubMed ID: 30323555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
    Yazici Y; Xie L; Ogbomo A; Ellis LA; Goyal K; Teeple A; Simsek I
    Biologics; 2018; 12():127-134. PubMed ID: 30498332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.
    Lin I; Melsheimer R; Bhak RH; Lefebvre P; DerSarkissian M; Emond B; Lax A; Nguyen C; Wu M; Young-Xu Y
    Curr Med Res Opin; 2022 Apr; 38(4):613-627. PubMed ID: 35125053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease.
    Kashima S; Sawada K; Moriichi K; Fujiya M
    Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
    Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
    Biologics; 2021; 15():1-15. PubMed ID: 33442230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
    Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
    Bokemeyer B; Hlavaty T; Allez M; Selema P; Moosavi S; Cadatal MJ; Fowler H; Mueller M; Liau KF; Gisbert JP
    Expert Opin Biol Ther; 2023; 23(8):791-800. PubMed ID: 37038897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
    Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
    Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.
    Milassin Á; Fábián A; Molnár T
    Therap Adv Gastroenterol; 2019; 12():1756284819842748. PubMed ID: 31019554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
    Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
    Morita A; Nishikawa K; Yamada F; Yamanaka K; Nakajima H; Ohtsuki M
    J Dermatol; 2022 Oct; 49(10):957-969. PubMed ID: 35799412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
    Mahakkanukrauh A; Chaiamnuay S; Koolvisoot A; Kitamnuayphong T; Manavathongchai S; Osiri M; Louthrenoo W; Uea-Areewongsa P; Ahn K; Jung N; Kim M; Lee S; Kim H; Kim S
    Immunotherapy; 2023 Oct; 15(14):1143-1155. PubMed ID: 37589164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
    Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.